Clinical trial
A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors
NCT02142803 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- May 20, 2014
- Completion date
- October 16, 2026
- Enrollment
- 50 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
adult glioblastoma, endometrial clear cell adenocarcinoma, endometrial serous adenocarcinoma, ovarian clear cell cystadenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian mucinous cystadenocarcinoma, ovarian serous cystadenocarcinoma, recurrent fallopian tube carcinoma, recurrent malignant uterine corpus neoplasm, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma, solid neoplasm, stage iiia fallopian tube cancer ajcc v7, stage iiia ovarian cancer ajcc v6 and v7, stage iiia primary peritoneal cancer ajcc v7, stage iiib fallopian tube cancer ajcc v7, stage iiib ovarian cancer ajcc v6 and v7, stage iiib primary peritoneal cancer ajcc v7, stage iiic fallopian tube cancer ajcc v7, stage iiic ovarian cancer ajcc v6 and v7, stage iiic primary peritoneal cancer ajcc v7, stage iv fallopian tube cancer ajcc v6 and v7, stage iv ovarian cancer ajcc v6 and v7, stage iv primary peritoneal cancer ajcc v7